Members,
This Past Sunday marked the Official End of 'Summer'...
More Meaningfully, it is the Beginning of the 'Fall' Season!
This means that Serious Traders are Back to Business; marking the Official Return of Big Volume and Liquidity to the Stock Exchanges...
This is Important in 'Penny Stocks' moreso than Anywhere Else, as this Boost in Trading Activity typically brings us an Abundance of HUGE Winners!
We were Incrediblely Fortunate this Summer with More Than +3,700% in Gains, however we believe the REALLY BIG WINNERS are going to Hit this 'Fall' starting with...
Bio-Matrix Scientific Group (BMSN) is a biotechnology company who, through its wholly owned subsidiary Regen BioPharma Inc., focuses on developing regenerative medical therapies and tools through the acquisition of patents and accelerating preclinical and clinical development.
The company’s goal is to develop a medical platform that focuses on the human therapies that have unmet medical needs through stem cell treatments that target internal organs such as the heart, lung, and circulatory system. To build this platform, BMSN has identified over 20,000 patents related to multiple stem cell therapeutics and has narrowed their list down to 2,000 U.S patents that may be commercially applied and has further identified 30 patents to be made available for licensing. With this process, the company is able to advance the preclinical, Phase I, and Phase II clinical trials and license these new technologies to other entities, universities, and institutions within one to two years of growth.
Currently, the company has acquired and begun the development of multiple stem cell therapies aimed at different diseases including:
- HemaXellerate – a U.S Food and Drug Administration approval pending cellular drug developed to stimulate the production of blood cells, heal injured bone marrow, and help patients with aplastic anemia.
- a New Gene Silencing Cancer Immunotherapy- stimulating the immune system to specifically inhibit the enzyme, known as gene silencing, that permits a tumor to escape the immune system in a non-toxic method.
Website(s): www.regenbiopharma.com
Over 1.5 Million People are Diagnosed with Cancer each Year in the U.S...
The overall Cost of Cancer Treatment is estimated to be $230 Billion per year!
While it is Sad and Unfortunately, these Numbers are True...
In Recent News, BMSN has Begun its Research Development for its new Breast Cancer Immunotherapy Product, known as dCellVax...
The company has also Recruited a Medical Pioneer in the RNA Interference (RNAi) field, Dr. David Suhy, to join BMSN’s Scientific Advisory Board!
BMSN has also Executed a License Agreement with Benitec BioPharma Ltd. for its Development of Gene Silencing technology...
Let's Take a Quick Look at BMSN's Year-to-Date Chart (Below)!

BMSN has shown us a Steady Climb in PPS since May...
...however, the REAL STORY comes into Play when you ZOOM IN!

After Today's HUGE News Release, we witnessed a +26.67% Increase in PPS!
Do you know what caused that Upward Explosion?
(Answer Answer Answer: News of BMSN's Breat Cancer Immunotherapeutic Product and an Increase in Trading Volume!)
That's Right... like we Told Your Before, the Summer is Done and Fall has Begun...
The Serious Traders are Back in their Office and their Grabbing Up Share of BMSN!
The Experts at Barchart.com have even Upgraded their Rating of BMSN to their Highest Rating of 'STRONG BUY' based on its Bullish Technical Indicators...
BMSN's Subpenny PPS of $0.0034 just seems Too Good To Be True!
We've already watched BMSN move up More Than +1,400% about 1-Year Ago...
Could Tomorrow be the start of its Next +1,000% Run?
We certainly Don't Want You to Miss Out on this Huge Profit Opportunity, that is why we are Urging All Members to immediately put BMSN on the Top of their Watch List, and be Ready Tomorrow @ 9:30am EST!
|